Coronary heart disease risk: Low-density lipoprotein and beyond

Trends Cardiovasc Med. 2022 May;32(4):181-194. doi: 10.1016/j.tcm.2021.04.002. Epub 2021 Apr 17.

Abstract

Coronary heart disease (CHD) is the leading cause of morbidity and mortality world-wide and has been characterized as a chronic immunoinflammatory, fibroproliferative disease fueled by lipids. Great advances have been made in elucidating the complex mechanistic interactions among risk factors associated with CHD, yielding abundant success towards preventive measures and the development of pharmaceuticals to prevent and treat CHD via attenuation of lipoprotein-mediated risk. However, significant residual risk remains. Several potentially modifiable CHD risk factors ostensibly contributing to this residual risk have since come to the fore, including systemic inflammation, diabetes mellitus, high-density lipoprotein, plasma triglycerides (TG) and remnant lipoproteins (RLP), lipoprotein(a) (Lp[a]), and vascular endothelial dysfunction (ED). Herein, we summarize the body of evidence implicating each of these risk factors in residual CHD risk.

Keywords: Atherosclerotic cardiovascular disease; Diabetes; Inflammation; Insulin resistance; Lipoprotein(a); Remnant lipoproteins; Triglycerides.

Publication types

  • Review

MeSH terms

  • Cholesterol
  • Coronary Disease* / diagnosis
  • Coronary Disease* / epidemiology
  • Coronary Disease* / prevention & control
  • Humans
  • Lipoprotein(a)
  • Lipoproteins, LDL*
  • Risk Factors
  • Triglycerides

Substances

  • Lipoprotein(a)
  • Lipoproteins, LDL
  • Triglycerides
  • Cholesterol